托拉塞米对顽固性心力衰竭患者胆红素及BNP的影响

Effect of Torasemide Refractory Heart Failure in Patients With Bilirubin and the BNP

目的探讨托拉塞米对顽固性心力衰竭患者心功能及预后的影响。方法选择心力衰竭患者72例,随机分为两组:托拉塞米治疗组和呋塞米治疗作为对照组,测定治疗前、治疗后7天胆红素及BNP浓度。结果两组治疗后胆红素和BNP浓度较治疗前下降,但托拉塞米治疗组下降更明显,与对照组比较差异均有统计学意义(P<0.05)。结论应用托拉塞米能降低顽固性心力衰竭患者胆红素和BNP水平,疗效明显。

Objective To investigate the effect of torasemide on cardiac function in patients with refractory heart failure and prognosis. Methods 72 patients with heart failure were randomly divided into two groups： the treatment group torasemide and furosemide treatment as the control group were measured before and after treatment for 7 days and BNP bilirubin concentrations. Results After treatment, bilirubin and BNP concentration than before treatment decreased, but torasemide treatment group decreased more significantly, compared with control group differences were statistically significant（P〈 0.05）. Conclusion Torasemide can reduce bilirubin and BNP levels in patients with refractory heart failure, significantly.